Julie Ho

Julie Ho

Auto-generated profile, based on publicly available information

Julie Ho

Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2012 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CWC. Wiebe
C. Wiebe
IGI. W. Gibson
I. W. Gibson
TBTom Blydt-Hansen
Tom Blydt-Hansen
MKM. Karpinski
M. Karpinski
JHJ. Ho
J. Ho
PNP. W. Nickerson
P. W. Nickerson
The natural history for patients with de novo donor‐specific antibodies (dnDSA) and the risk factors for its development have not been well defined. Furthermore, clinical and histologic correlation with serologic data is limited. We studied 315 consecutive renal transplants without pretransplant DSA, with a mean follow‐up of 6.2 ± 2.9 years. Protocol (n = 215) and for cause (n = 163) biopsies were analyzed. Solid phase assays were used to screen for dnDSA posttransplant. A total of 47 out of 315 (15%) patients developed dnDSA at a mean of 4.6 ± 3.0 years posttransplant. Independent predictors of dnDSA were HLA‐DRβ1 MM > 0 (OR 5.66, p < 0.006); and nonadherence (OR 8.75, p < 0.001); with a strong trend toward clinical rejection episodes preceding dnDSA (OR 1.57 per rejection episode, p = 0.061). The median 10‐year graft survival for those with dnDSA was lower than the No dnDSA group (57% vs. 96%, p < 0.0001). Pathology consistent with antibody‐mediated injury can occur and progress in patients with dnDSA in the absence of graft dysfunction and furthermore, nonadherence and cellular rejection contribute to dnDSA development and progression to graft loss.

25 October 2013 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CWC. Wiebe
C. Wiebe
DPD. Pochinco
D. Pochinco
TBTom Blydt-Hansen
Tom Blydt-Hansen
JHJ. Ho
J. Ho
PBP. E. Birk
P. E. Birk
PNP. W. Nickerson
P. W. Nickerson
De novo donor‐specific antibody (dnDSA) develops in 15–25% of renal transplant recipients within 5 years of transplantation and is associated with 40% lower graft survival at 10 years. HLA epitope matching is a novel strategy that may minimize dnDSA development. HLAMatchmaker software was used to characterize epitope mismatches at 395 potential HLA‐DR/DQ/DP conformational epitopes for 286 donor–recipient pairs. Epitope specificities were assigned using single antigen HLA bead analysis and correlated with known monoclonal alloantibody epitope targets. Locus‐specific epitope mismatches were more numerous in patients who developed HLA‐DR dnDSA alone (21.4 vs. 13.2, p < 0.02) or HLA‐DQ dnDSA alone (27.5 vs. 17.3, p < 0.001). An optimal threshold for epitope mismatches (10 for HLA‐DR, 17 for HLA‐DQ) was defined that was associated with minimal development of Class II dnDSA. Applying these thresholds, zero and 2.7% of patients developed dnDSA against HLA‐DR and HLA‐DQ, respectively, after a median of 6.9 years. Epitope specificity analysis revealed that 3 HLA‐DR and 3 HLA‐DQ epitopes were independent multivariate predictors of Class II dnDSA. HLA‐DR and DQ epitope matching outperforms traditional low‐resolution antigen‐based matching and has the potential to minimize the risk of de novo Class II DSA development, thereby improving long‐term graft outcome.

10 June 2015 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CWC. Wiebe
C. Wiebe
IGI. W. Gibson
I. W. Gibson
TBTom Blydt-Hansen
Tom Blydt-Hansen
DPD. Pochinco
D. Pochinco
PBP. E. Birk
P. E. Birk
PNP. W. Nickerson
P. W. Nickerson
Understanding rates and determinants of clinical pathologic progression for recipients with de novo donor‐specific antibody (dnDSA), especially subclinical dnDSA, may identify surrogate endpoints and inform clinical trial design. A consecutive cohort of 508 renal transplant recipients (n = 64 with dnDSA) was studied. Recipients (n = 388) without dnDSA or dysfunction had an eGFR decline of −0.65 mL/min/1.73 m2/year. In recipients with dnDSA, the rate eGFR decline was significantly increased prior to dnDSA onset (−2.89 vs. −0.65 mL/min/1.73 m2/year, p < 0.0001) and accelerated post‐dnDSA (−3.63 vs. −2.89 mL/min/1.73 m2/year, p < 0.0001), suggesting that dnDSA is both a marker and contributor to ongoing alloimmunity. Time to 50% post‐dnDSA graft loss was longer in recipients with subclinical versus a clinical dnDSA phenotype (8.3 vs. 3.3 years, p < 0.0001). Analysis of 1091 allograft biopsies found that dnDSA and time independently predicted chronic glomerulopathy (cg), but not interstitial fibrosis and tubular atrophy (IFTA). Early T cell–mediated rejection, nonadherence, and time were multivariate predictors of IFTA. Independent risk factors for post‐dnDSA graft survival available prior to, or at the time of, dnDSA detection were delayed graft function, nonadherence, dnDSA mean fluorescence intensity sum score, tubulitis, and cg. Ultimately, dnDSA is part of a continuum of mixed alloimmune‐mediated injury, which requires solutions targeting T and B cells.

1 December 2015 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
PDF file
JHJulie Ho
Julie Ho
NTNavdeep Tangri
Navdeep Tangri
PKPaul Komenda
Paul Komenda
AKAmit Kaushal
Amit Kaushal
MSManish M Sood
Manish M Sood
CRClaudio Rigatto
Claudio Rigatto
Background Early accurate detection of acute kidney injury (AKI) occurring after cardiac surgery may improve morbidity and mortality. Although several novel biomarkers have been developed for the early detection of AKI, their clinical utility in the critical intraoperative and immediate postoperative period remains unclear. Study Design Systematic review and meta-analysis. Setting & Population Adult patients having cardiac surgery. Selection Criteria for Studies EMBASE, CINAHL, Cochrane Library, Scopus, and PubMed from January 1990 until January 2015 were systematically searched for cohort studies reporting the utility of novel biomarkers for the early diagnosis of AKI after adult cardiac surgery. Reviewers extracted data for study design, population, timing of biomarker measurement and AKI occurrence, biomarker performance (area under the receiver operating characteristic curve [AUROC]), and risk of bias. Index Tests Novel urine, plasma, and serum AKI biomarkers, measured intraoperatively and in the early postoperative period (<24 hours). Reference Tests AKI was defined according to the RIFLE, AKIN, or 2012 KDIGO criteria. Results We found 28 studies reporting intraoperative and/or early postoperative measurement of urine (n = 23 studies) or plasma or serum (n = 12 studies) biomarkers. Only 4 of these studies measured biomarkers intraoperatively. Overall, intraoperative discrimination by the urine biomarkers neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury marker 1 (KIM-1) demonstrated AUROCs < 0.70, whereas N-acetyl-β-d-glucosaminidase (NAG) and cystatin C had AUROCs < 0.75. In the immediate 24-hour postoperative period, the urine biomarkers NGAL (16 studies), KIM-1 (6 studies), and liver-type fatty acid binding protein (6 studies) exhibited composite AUROCs of 0.69 to 0.72. The composite AUROCs for postoperative urine cystatin C, NAG, and interleukin 18 were ≤0.70. Similarly, the composite AUROCs for postoperative plasma NGAL (6 studies) and cystatin-C (5 studies) were <0.70. Limitations Heterogeneous AKI definitions. Conclusions In adults, known urinary, plasma, and serum biomarkers of AKI possess modest discrimination at best when measured within 24 hours of cardiac surgery.

1 December 2003 in Critical Care Medicine
Verified
Journal Article
Closed access
JHJuliet Ho
Juliet Ho
WSWilliam J. Sibbald
William J. Sibbald
ICIan H. Chin-Yee
Ian H. Chin-Yee
To review the literature on red blood cell storage and its relationship to the efficacy of transfusion. Well-documented changes occur to the red blood cell product during ex vivo storage. These changes include a reduction in red blood cell deformability, altered red blood cell adhesiveness and aggregability, and a reduction in 2,3-diphosphoglycerate and ATP. Bioactive compounds with proinflammatory effects also accumulate in the storage medium. These changes reduce posttransfusion viability of red blood cells. The clinical effects beyond posttransfusion viability are uncertain, but a growing body of evidence suggests that the storage lesion may reduce tissue oxygen availability, have proinflammatory and immunomodulatory effects, and influence morbidity and mortality. There are no published randomized, control trials examining the effect of storage duration on morbidity and mortality. Leukoreduction improves the quality of stored red blood cell products and in some studies has been shown to reduce morbidity and mortality. Although storage duration influences the quality of red blood cell product, there is currently insufficient evidence to advocate shorter storage periods for red blood cell products.

1 April 2009 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
JHJulie Ho
Julie Ho
MLMalcolm Lucy
Malcolm Lucy
OKOleg Krokhin
Oleg Krokhin
KHKent Hayglass
Kent Hayglass
EPEdward Pascoe
Edward Pascoe
MRMartina Reslerova
Martina Reslerova